Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
Information source: Inspire Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Conjunctivitis
Intervention: Epinastine HCl (Drug); Olopatadine HCl (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Inspire Pharmaceuticals Official(s) and/or principal investigator(s):
Michael Raizman, MD, Principal Investigator, Affiliation: Ophthalmic Consultants of Boston
Summary
The purpose of this study is to compare the effects of two marked ocular anti-allergy
medications in cat sensitive subjects with allergic conjunctivitis.
Clinical Details
Official title: A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model
Study design: Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Primary outcome: Change in ocular itch score from baseline
Secondary outcome: Ocular comfort score
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Documented history of ocular allergy to cats.
- Positive skin prick allergen reaction to cat dander.
Exclusion Criteria:
- Use of any topical or systemic corticosteroids, immunosuppressive agents,
antihistamines, decongestants, NSAIDs, or asprin during the two weeks prior to
enrollment into the study.
- History of severe asthma, reactive airway disease or bronchial obstruction.
- Ocular surgery or trauma in the last year.
Locations and Contacts
Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, United States
Additional Information
Starting date: October 2007
Last updated: May 14, 2008
|
